BioCentury | Sep 12, 2011
Clinical News

DRL-17822: Phase II started

...and 300 mg DRL-17822 for 4 weeks. Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Product: DRL-17822...
BioCentury | Jun 1, 2009
Clinical News

DRL 17822: Phase I started

Dr. Reddy's began a double-blind, placebo-controlled, European Phase I trial to evaluate DRL 17822 in healthy volunteers. Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Product: DRL 17822 Business: Metabolic Molecular target: Cholesteryl ester transfer protein...
Items per page:
1 - 2 of 2